Maven Securities’s Arbutus Biopharma ABUS Stock Holding History

Maven Securities’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,890	Closed	-$40K	–	1011
2021 Q1	$40K	Buy	+11,890	New	+$45.9K	﹤0.01%	1103

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Maven Securities's ABUS Position: Q2 2021 in Review

Maven Securities sold out of Arbutus Biopharma (ABUS) in Q2 2021, closing a stake of 11,890 shares — an estimated $40K sold.

Maven Securities first reported a position in ABUS in Q1 2021 and held it in 1 quarter. The position peaked at $40K in Q1 2021. 91 funds tracked by Wall St. Rank hold ABUS as of Q2 2021.

Maven Securities reported no remaining Arbutus Biopharma position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 11,890 Arbutus Biopharma shares in Q2 2021, an estimated $40K.
Maven Securities first reported a position in Arbutus Biopharma in Q1 2021 and held it in 1 quarter.
Maven Securities's Arbutus Biopharma position peaked at $40K in Q1 2021.
91 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.